Your session is about to expire
← Back to Search
Pembrolizumab + Chemotherapy for Hodgkin's Lymphoma
Study Summary
This trial studies a combination of chemotherapy & a new drug to treat newly diagnosed Hodgkins Lymphoma. The goal is to see if the new drug improves treatment outcomes.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My diagnosis is classical Hodgkin lymphoma, confirmed by a specific WHO classification.I haven't had chemotherapy, targeted therapy, or radiation in the last 2 weeks.I agree to use birth control to prevent pregnancy during the study.I have an immune system disorder or have taken steroids in the last week.I do not have uncontrolled heart conditions like heart failure or irregular heartbeat.I do not have any active infections needing treatment, except for simple UTIs.I have an active case of tuberculosis.I have another cancer that is getting worse or needs treatment.My organs and bone marrow are functioning well.I have previously been treated with drugs targeting PD-1, PD-L1, or PD-L2.I have not received a live vaccine in the last 30 days.I have active hepatitis B or C.My cancer can be at any stage and severity.I have a history of or currently have non-infectious lung inflammation.I am fully active or can carry out light work.My disease has not been treated, except for a short course of corticosteroids.
- Group 1: Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 10 Other Conditions - This treatment demonstrated efficacy for 10 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any locations in North America that are actively engaged with this experiment?
"Currently, 4 distinct sites are hosting the trial. These include Atlanta, Chicago and Stanford among others. To reduce travel-related hassles during your participation in this study, we advise you select a location nearest to you."
For which conditions are FDG-PET/CT, pembrolizumab and chemotherapy most commonly prescribed?
"Malignant neoplasms can be treated with a variety of medical interventions, such as FDG-PET/CT scans, pembrolizumab, and chemotherapy. Moreover, these treatments have been found to be beneficial for patients suffering from unresectable melanoma, microsatellite instability high states, or neuroblastoma (nb)."
How successful have pembrolizumab, chemotherapy and FDG-PET/CT been in past trials?
"Currently, 1,217 studies are being conducted to assess Treatment (FDG-PET/CT, pembrolizumab, chemotherapy); of these trials, 235 have advanced into the last phase. Although most investigations take place in Houston, Texas there is a total of 59,775 clinical trial sites around the world that are pursuing this treatment."
Could you please explain the risks associated with this combination of FDG-PET/CT, pembrolizumab, and chemotherapy?
"Based on our evaluation, Treatment (FDG-PET/CT, pembrolizumab, chemotherapy) was assigned a value of 2. This is because the Phase 2 trial provides evidence that this treatment is safe but lacks any data regarding its efficacy."
Is this research accepting new participants at the present time?
"This research project, which was unveiled on November 9th 2017 and last revised on July 1st 2020, is not currently recruiting patients. However, there are 2918 other trials actively looking for volunteers at this time."
How extensive is the current enrolment for this clinical research project?
"Unfortunately, this trial has ceased recruitment activities. It first appeared on the 11th of September 2017 but was last updated on July 1st 2020. For those searching for similar trials, there are presently 1701 active studies recruiting Hodgkin's lymphoma patients and 1217 clinical trials investigating Treatment (FDG-PET/CT, pembrolizumab, chemotherapy)."
Is this research a groundbreaking endeavor?
"At the present, 1217 treatments (including FDG-PET/CT, pembrolizumab, and chemotherapy) are actively being studied in 73 countries across 3454 cities. The earliest of such studies was conducted by Alfacell back in 1997 with 300 participants who completed phase 3 drug approval; since then 1677 similar trials have been launched."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger